Evaluation of CEA, CA19-9 and SPan-1 as tumor markers for colorectal cancer.

概要

論文の詳細を見る
The clinical evaluations of serum CEA, CA19-9 and SPan-1 levels were studied in 109 patients with colorectal cancers. Positive rates of CEA, CA19-9 and SPan-1 were 40.4 %, 23.9% and 25.7% respectively. Positive rates of CEA in stage II III and IV were almost similar. Positive rates of CA19-9 rose in accordance with advanced histological stages. A positive rate of Span-1 was 25% in stage I, higher than those of CEA and CA19-9 in stage I, and positive rates of SPan-1 in stage IV and V were higher than in stage I, II and II. While a positive rate of CEA was only 40.4%, a combination assay of CEA and CA19-9 or SPan-1 increased to a positive rate of 51.4% or 55.6%. The most sensitive tumor marker in colorectal cancer was CEA. And moreover, a combination assay o CEA and CA19-9 or SPan-1 was considered to be useful for the serum diagnosis of colorectal cancer.
日本大腸肛門病学会の論文